QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Best Stocks Under $50.00 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $50.00 (50 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


JD Sports Fashion stock logo

#1 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $2.39 (+$0.04)
Average Trading Volume: 2,471 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $203.33 (8,407.7% Upside)
JD Sports Fashion Plc retails and distributes sports fashion wear and outdoor clothing and equipment. It operates through the Sports Fashion and Outdoor segments. The Sports Fashion segment consists of JD Sports Fashion Plc, John David Sports Fashion (Ireland) Limited, Spodis SA, Champion Sports Ireland, JD Sprinter Holdings 2010 SL, JD Sports Fashion BV, JD Sports Fashion Germany GmbH, JD Sports Fashion SRL, Duffer of St George Limited, Topgrade Sportswear Limited, Kooga Rugby Limited, Focus Brands Limited, Kukri Sports Limited, Source Lab Limited, R.D. Scott Limited, Tessuti Group Limited, Nicholas Deakins Limited, Cloggs Online Limited, Ark Fashion Limited and Mainline Menswear Limited. The Outdoor segment consists of Blacks Outdoor Retail Ltd. Tiso Group Ltd and ActivInstinct Limited. The company was founded by John Carruthers Wardle and David Martin Makin in 1981 and is headquartered in Bury, the United Kingdom.
Northland Power stock logo

#2 - Northland Power

OTCMKTS:NPIFF
Stock Price: $21.81 (-$0.59)
PE Ratio: -68.99
Average Trading Volume: 9,754 shares
Dividend Yield: 7.24%
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $50.75 (132.7% Upside)
Northland Power, Inc. engages in the development, building, owning, and management of wind facilities. It operates through the following segments: Offshore Wind, Efficient Natural Gas, Onshore Renewable, Utility, and Other. The Offshore Wind segment consists of Gemini, Nordsee One, and Deutsche Bucht projects. The Onshore Renewables segment consists of Solar, Grand Bend, Jardin, Mont Louis, Cochrane, McLeans, and La Lucha projects. The Efficient Natural Gas includes North Battleford, Iroquois Falls, Kirkland Lake, Kingston, Thorold, and Spy Hill projects. The Utility segment operates Empresa de Energía de Boyacá S.A E.S.P. (EBSA) project. The Other segment focuses on investment income and administration activities. The company was founded by James C. Temerty in 1987 and is headquartered in Toronto, Canada.
Mirum Pharmaceuticals stock logo

#3 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price: $26.05 (-$0.12)
PE Ratio: -7.14
Market Cap: $990.68 million
Average Trading Volume: 448,126 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.00 (88.1% Upside)
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Ocular Therapeutix stock logo

#4 - Ocular Therapeutix

NASDAQ:OCUL
Stock Price: $6.37 (-$0.01)
PE Ratio: -5.35
Market Cap: $493.87 million
Average Trading Volume: 1.30 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.80 (100.9% Upside)
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Everi stock logo

#5 - Everi

NYSE:EVRI
Stock Price: $14.72 (+$0.04)
PE Ratio: 12.17
Market Cap: $1.31 billion
Average Trading Volume: 747,942 shares
P/E Ratio: 12.2
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $26.20 (78.0% Upside)
Everi Holdings, Inc. engages in the provision of technology solutions to the casino, interactive, and gaming industry. It operates through the Games and Financial Technology Solutions (FinTech) segments. The Games segment focuses on leased gaming equipment, sales of gaming equipment, gaming systems, interactive solutions, and ancillary products and services. The FinTech segment provides access to cash at gaming facilities via ATM cash withdrawals, credit card cash access transactions and point of sale debit card cash access transactions, check-related services, fully integrated kiosks and maintenance services, compliance, audit and data software, casino credit data, and reporting services and other ancillary offerings. The company was founded on February 4, 2004 and is headquartered in Las Vegas, NV.
Dyne Therapeutics stock logo

#6 - Dyne Therapeutics

NASDAQ:DYN
Stock Price: $13.16 (-$0.41)
PE Ratio: -3.95
Market Cap: $767.36 million
Average Trading Volume: 349,746 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.83 (96.3% Upside)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
InflaRx stock logo

#7 - InflaRx

NASDAQ:IFRX
Stock Price: $4.37 (-$0.38)
PE Ratio: -7.05
Market Cap: $195.34 million
Average Trading Volume: 1.66 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (220.4% Upside)
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Avidity Biosciences stock logo

#8 - Avidity Biosciences

NASDAQ:RNA
Stock Price: $10.69 (-$0.32)
PE Ratio: -3.18
Market Cap: $757.07 million
Average Trading Volume: 1.15 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $42.60 (298.5% Upside)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Skyward Specialty Insurance Group stock logo

#9 - Skyward Specialty Insurance Group

NASDAQ:SKWD
Stock Price: $24.06 (-$0.11)
Market Cap: $906.05 million
Average Trading Volume: 194,037 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $26.67 (10.8% Upside)
Skyward Specialty Insurance Group Inc. is an insurance holding company, engages in underwriting commercial property and casualty insurance coverages principally in the United States. Skyward Specialty Insurance Group Inc. is based in Houston, Texas.
CymaBay Therapeutics stock logo

#10 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $9.05 (-$0.11)
PE Ratio: -7.67
Market Cap: $882.47 million
Average Trading Volume: 1.65 million shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.57 (61.0% Upside)
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Graphic Packaging stock logo

#11 - Graphic Packaging

NYSE:GPK
Stock Price: $25.63 (-$0.14)
PE Ratio: 12.82
Market Cap: $7.87 billion
Average Trading Volume: 3.11 million shares
P/E Ratio: 12.8
Dividend Yield: 1.57%
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $28.78 (12.3% Upside)
Graphic Packaging Holding Co. engages in the provision of paper-based packaging solutions for a variety of products to food, beverage and other consumer products companies. It operates through the following business segments: Paperboard Mills, Americas Paperboard Packaging, Europe Paperboard Packaging, and Corporate and Other. The Paperboard Mills segment includes the eight North American paperboard mills which produce coated unbleached kraft paperboard and coated-recycled paperboard. The Americas Paperboard Packaging segment consists of paperboard folding cartons sold to consumer-packaged goods companies serving the food, beverage and consumer product markets in the Americas. The Europe Paperboard Packaging segment provides paperboard folding cartons sold to consumer-packaged goods companies serving the food, beverage and consumer product markets in Europe. The Corporate and Other segment deals with the Pacific Rim and Australia operating segments and unallocated corporate and one-time costs. The company was founded on December 28, 1992, and is headquartered in Atlanta, GA.
89bio stock logo

#12 - 89bio

NASDAQ:ETNB
Stock Price: $16.91 (-$0.73)
PE Ratio: -6.00
Market Cap: $1.23 billion
Average Trading Volume: 1.81 million shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $34.00 (101.1% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Energy Transfer stock logo

#13 - Energy Transfer

NYSE:ET
Stock Price: $12.72 (+$0.19)
PE Ratio: 9.49
Market Cap: $39.96 billion
Average Trading Volume: 12.16 million shares
P/E Ratio: 9.5
Dividend Yield: 9.87%
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.43 (29.2% Upside)
Energy Transfer LP provides natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acq
Atlas Energy Solutions stock logo

#14 - Atlas Energy Solutions

NYSE:AESI
Stock Price: $17.54 (+$0.03)
Market Cap: $1.75 billion
Average Trading Volume: 481,299 shares
Dividend Yield: 0.86%
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.44 (39.4% Upside)
Atlas Energy Solutions Inc. is a provider of proppant and logistics services to customers engaged in the oil and natural gas industry principally within the Permian Basin of West Texas and New Mexico. Atlas Energy Solutions Inc. is based in AUSTIN, Texas.
Xencor stock logo

#15 - Xencor

NASDAQ:XNCR
Stock Price: $26.05 (-$0.46)
PE Ratio: -11.13
Market Cap: $1.57 billion
Average Trading Volume: 350,106 shares
Consensus Rating: Buy (11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $45.33 (74.0% Upside)
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Xenon Pharmaceuticals stock logo

#16 - Xenon Pharmaceuticals

NASDAQ:XENE
Stock Price: $40.77 (-$0.54)
PE Ratio: -17.57
Market Cap: $2.59 billion
Average Trading Volume: 401,807 shares
Consensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $51.50 (26.3% Upside)
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Halliburton stock logo

#17 - Halliburton

NYSE:HAL
Stock Price: $29.87 (+$0.93)
PE Ratio: 13.83
Market Cap: $26.95 billion
Average Trading Volume: 9.43 million shares
P/E Ratio: 13.8
Dividend Yield: 2.30%
Consensus Rating: Buy (14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $48.24 (61.5% Upside)
Halliburton Co. engages in the provision of services and products to the energy industry related to the exploration, development, and production of oil and natural gas. It operates through the Completion and Production, and Drilling and Evaluation segments. The Completion and Production segment delivers cementing, stimulation, intervention, pressure control, specialty chemicals, artificial lift, and completion services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, evaluation, and wellbore placement solutions that enable customers to model, measure, and optimize their well construction activities. The company was founded by Erle P. Halliburton in 1919 and is headquartered in Houston, TX.
Paragon 28 stock logo

#18 - Paragon 28

NYSE:FNA
Stock Price: $18.48 (+$0.30)
PE Ratio: -21.00
Market Cap: $1.52 billion
Average Trading Volume: 352,971 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.67 (49.7% Upside)
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Verona Pharma stock logo

#19 - Verona Pharma

NASDAQ:VRNA
Stock Price: $19.41 (-$0.02)
PE Ratio: -20.22
Market Cap: $1.53 billion
Average Trading Volume: 587,077 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $29.33 (51.1% Upside)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Disc Medicine Opco stock logo

#20 - Disc Medicine Opco

NASDAQ:IRON
Stock Price: $33.58 (-$0.47)
Market Cap: $637.95 million
Average Trading Volume: 94,774 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.88 (15.8% Upside)
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. Disc Medicine, Inc. is based in Watertown, Massachusetts.
Natera stock logo

#21 - Natera

NASDAQ:NTRA
Stock Price: $49.64
PE Ratio: -9.28
Market Cap: $5.67 billion
Average Trading Volume: 1.33 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $74.89 (50.9% Upside)
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Pan American Silver stock logo

#22 - Pan American Silver

NYSE:PAAS
Stock Price: $15.69 (-$0.60)
PE Ratio: -9.63
Market Cap: $3.31 billion
Average Trading Volume: 4.52 million shares
Dividend Yield: 3.08%
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.50 (62.5% Upside)
Pan American Silver Corp. engages in the operation, development, and exploration of silver and gold producing properties and assets. It operates through the Silver and Gold segments. The company was founded by Ross J. Beaty and John H. Wright on March 17, 1979 and is headquartered in Vancouver, Canada.
RAPT Therapeutics stock logo

#23 - RAPT Therapeutics

NASDAQ:RAPT
Stock Price: $20.09 (-$0.96)
PE Ratio: -7.58
Market Cap: $690.09 million
Average Trading Volume: 453,589 shares
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $41.22 (105.2% Upside)
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
California Resources stock logo

#24 - California Resources

NYSE:CRC
Stock Price: $39.77 (+$0.37)
PE Ratio: 3.02
Market Cap: $2.81 billion
Average Trading Volume: 731,241 shares
P/E Ratio: 3.0
Dividend Yield: 2.92%
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $56.00 (40.8% Upside)
California Resources Corporation operates as an independent oil and natural gas company. The company explores for, produces, gathers, processes, and markets crude oil, natural gas, and natural gas liquids for marketers, California refineries, and other purchasers that have access to transportation and storage facilities. As of December 31, 2021, it had interests in approximately 1.9 million net mineral acres with proved reserves totaled an estimated 480 million barrels of oil equivalent. The company also engages in the generation and sale of electricity to the local utility and the grid. The company was incorporated in 2014 and is based in Santa Clarita, California.
Constellium stock logo

#25 - Constellium

NYSE:CSTM
Stock Price: $16.05 (+$0.14)
PE Ratio: 16.38
Market Cap: $2.32 billion
Average Trading Volume: 1.01 million shares
P/E Ratio: 16.4
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $20.00 (24.6% Upside)
Constellium SE operates as a holding company with interest in the design and manufacture of a range of specialty rolled, and extruded aluminum products, serving primarily the aerospace, packaging and automotive end-markets. The company operates through the following segments: Packaging and Automotive Rolled Products, Aerospace and Transportation, and Automotive Structures and Industry. The Packaging and Automotive Rolled Products segment includes the production of rolled aluminum products. The Aerospace and Transportation segment is involved in the production of rolled and extruded aluminum products for the aerospace market, as well as rolled products for transport and industry end-uses. The Automotive Structures and Industry segment offers crash-management systems, body structures and side impact beams in Germany, North America and China. The company was founded on May 14, 2010 and is headquartered in Paris, France.

More Stock Ideas from MarketBeat

My Account -